Recent Developments in Human Umbilical Cord Blood Transplantation in Israel  by Nagler, Arnon
From theH
Medic
Financial d
Correspon
ment
Hosp
nagler
1083-8791
doi:10.101Recent Developments in Human Umbilical Cord Blood
Transplantation in Israel
Arnon NaglerHISTORICAL BACKGROUND
Human umbilical cord blood (HUCB) has estab-
lished itself as a legitimate source for hematopoeitic
stem cell transplantation. The first unrelated cord
blood bank (CBB) in Israel was established in 1992 at
the Hadassah Medical Center. The first related cord
blood transplant (CBT) was performed in 1994 in
a girl with b-thalaasemia major from her sister’s
UCB; the graft was harvested and cryopreserved in
the local CBB. In 1996, we performed the first unre-
lated CBT in a boy with adrenoleukodystrophy using
an unrelated cord blood from the NY CBB. In 2002,
we performed the first CBT in Israel using preimplan-
tation genetic diagnosis for an HLA-matched donor in
a child with Fanconi’s anemia (FA). In 2006, the first
adult double CBT was carried out in Israel.
At present, there are 2 public CBBs in Israel. One is
located in Sheba, which is an American Association of
Blood Bank (AABB) andNationalMarrowDonor Pro-
gram (NMDP)-accredited CBB, and has already pro-
vided 16 UCB units for transplantation. The other
public CBB is located at the Hadassah Medical Center
in Jerusalem.TRANSPLANTATION OF CB
In the Chaim Sheba Medical Center, 31 CBT have
been performed to date: 22 in children and 9 in adults
(Table 1). Twenty-two were single CBT, whereas 9
were double CBT. All adults were transplanted with
2 UCB units. Thirteen patients were transplanted
for genetic disease, whereas 18 for hematologic malig-
nancies. Nineteen patients were transplanted from
unrelated donor and 12 from family donors. WithematologyDivision and Cord Blood Bank, Chaim Sheba
al Center, Tel Hashomer 52621, Israel.
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6/j.bbmt.2008.10.017a median follow up of 13.5 (2-93) months, 17 patients
(55%) are alive (2 with relapse); whereas 14 have died:
9 from treatment-related mortality (30% TRM) and 5
from relapse (Table 2).INNOVATIONS IN CBT
Compared to bonemarrow transplants, cord blood
collection is easier and safer. However, although
HUCB is an attractive alternative source of hemato-
poietic stem cells (HSCs) for allogeneic transplanta-
tion (allo-SCT), its major disadvantage is the
relatively low number of HSCs and delayed engraft-
ment.
We have developed some innovative approaches
with the aim (1) to try to increase and preserve the
number of stem/progenitor cell HUCB units and (2)
to overcome the 20% to 30% of cells loss while thaw-
ing the cryopreserved HUCB cells.
We have developed a closed, sterile disposable sys-
tem that enables the ‘‘semi’’ controlled collection of
HUCB, overcoming the bottleneck of the umbilical
vein and the collection needle, thus enabling easier
flow of the blood and eliminating the need for a rather
prolonged learning curve by the midwives in the deliv-
ery room. The device (SituGen) is now in phase I
clinical trial.
New Technique for Cryopreservation of the
UCB
Currently, most of the CBB cryopreserve HUCB
units as a mononuclear cell (MNC) fraction using di-
methylsulfoxide (DMSO), which results in a 20% to
30% cell loss on thawing. One way to avoid this
problems is by lyophilization. Lyophilization is a pro-
cess in which ice crystals sublimate resulting in a dry,
stable, and low-weight sample. We have developed
a freezing apparatus called the Multi Thermal Gradi-
ent (MTG) device. This device is based on the direc-
tional freezing technology, and enables the precise
control of ice crystal morphology during the freezing
process, thus making the use of intracellular cryopro-
tectant agents (CPAs) such as DMSO redundant. The
aim of our study was to find out whether lyophilized
MNC rehydrated with pure water are able to99
Table 1. Cord Blood Stem Cell Transplantation (Tel Hashomer Medical Center 1996-2008): Characteristics of Recipients and
Donors
Pt. No. Diagnosis Age at Tx (years) Donor HLA MM Conditioning Protocol
Infused Cells
CD34 105/kg NC 107/kg
1 SCID 0.25 MRD 0 None 50 65
2 Thalassemia 14 MRD 0 Bu/Cy/ATG 0.87 0.004
3 FA 9 MRD 0 Bu/Cy/ATG 3.1 13.9
4 Hurler 1.75 MRD 0 Bu/Cy/ATG 2.1 NE
5 FA 10 MRD 0 Flu/Cy 0.65 NE
6 FA 3.5 MRD 0 Flu/Cy 7.6 2.3
7 CAMT 2.5 URD 1 Flu/Cy/Bu/ATG 9.5 9.1
8 ALL—Ph+ 14.5 URD 1 Flu/Cy/Bu/ATG 3.0 0.9
9 ALL relapse 10.5 MRD 0 TBI/VP-16 1.3 3.4
10 WAS 0.5 URD 1 Bu/Flu/ATG 2.2 32
11 MDS 6.5 URD 2 Bu/Cy/ATG 3.9 8
12 CGD (2 CB Tx) 8 URD 0 Bu/Flu/ATG 2.8 4.8
9 URD 0 Bu/Flu/ATG 4 1.78
13 JMML (2 CB Tx) 4 URD 1 Bu/Cyu/Mel/ATG 98.7 1.1
4.25 URD 1 Bu/Cy/Mel/ATG 6.33 12
14 AML 0.5 URD 1 Bu/Cy/ATG 7.2 4.7
15 Thalassemia 13 MRD 1 Bu/Flu/TT 1.7 0.39
16 ALCL 15 MRD 1 ATG/Flu/Mel/TT 2.0 0.3
17 HLH 1.8 MUD 0 Bu/Flu/ATG 10 9
18 Osteopetrosis 1.8 MUD 0 Bu/Cy/ATG 7 29
19 ALL relapse 6 MRD 0 TBI/VP-16 3.9 1.5
20 ALL relapse 2nd Tx post-Haplo 15.5 DCB 2
2
Bu/Cy/ATG 7.9 7.6
21 Thalassemia 0.3 MRD 0 Bu/Flu/TT 1.7 0.4
22 NHL 14 MRD 1 Mel/Flu/TT 2.9 1.5
23 AML 27 DCB 3
3
Mel/Flu 2.0
2.6
3.5
24 MDS 47 DCB 2
2
Mel/Flu/Thiotepa 2.0
1.8
0.9
25 ALL 59 DCB 2
2
Mel/Flu/Thiotepa 1.3
1.9
1.5
26 AML 30 DCB 0
1
TBI/CTX/Flu 2.4
2.8
2.3
27 ALL 21 DCB 2
3
TBI/CTX/Flu 3.1
1.7
3.7
28 AML 65 DCB 2
3
TBI/CTX/Flu 3.6
3.1
5.2
29 AML 57 DCB 1
2
Mel/Flu 2.5
1.2
2.0
30 AML 58 DCB 2
2
Mel/Flu/ATG 2.3
1.9
5.2
31 AML 56 DCB 2 TBI/CTX/Flu NA 4.2
ALCL indicates anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, antithymocytic globulin;
Bu, Busulfan; CAMT, congenital amegakaryocytic; CB, cord blood; CGD, chronic granulomatous disease; CRY, cryopreserved; Cy, cyclophosphamide;
d, days; DCB, double cord blood (from MUDs); dis., discharge; Inf, infused; FA, Fanconi anemia; Flu, fludarabine; HLH, hemophagocytic lymphohistio-
cytosis; JMML, juvenile melomonocytic leukemia; Lim, limited; m, months; MDS, myelodysplastic syndrome; Mel, Melphalan; MRD, matched related
donor; NE, not evaluated; URD, unrelated donor; SCID, severe combined immunedeficiency; TBI, total body irradiation; TRM, treatment-related
mortality; Tx,transplantation(s); y, years; WAS, Wiskot Aldrich Syndrome.
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sented mothers were split into 2 portions, and a com-
parison between fresh unmanipulated HUCB cells
and cells that underwent lyophilization and rehydra-
tion was performed. The MNC fraction was sepa-
rated on a Ficoll-Hypaque gradient. A freezing
solution called IMT-2 was added to the cell pellets
and 2.5 mL of the cell suspension were put in a glass
test tube and frozen using the MTG-516 freezing ap-
paratus. After freezing, samples were placed in a com-
mercial lyophilizer for 3.5 days. Rehydration was
done by adding 2.4 mL of double-distilled water
(DDW) prewarmed to 37C. After lyophilization
and rehydration samples were evaluated for viabilityand CD341 cell number. Viability was assayed by
live/dead fluorescein stains using SYBR/PI. Granulo-
cyte macrophage colony-forming unit (GM-CFU)
frequencies were assessed in semisolid cultures and
CD341 expression was assessed by a fluorescent acti-
vated cell sorter (FACS) and compared to the unma-
nipulated fraction. We found that viability after
lyophilization was 89.21 6 1.5% compared to fresh
CB cells and the number of CD341 cells was 15,600
cells/mL before freezing and 17,450 6 150 cells/mL
after lyophilization, showing that the HUCB HSC
survived complete desiccation. Total number of colo-
nies (GM 1 E) was 31 6 21.15 and 23.3 6 13.9 for
unmanipulated and postlyophilization-rehydration
Table 2. Engraftment, Chimerism, Incidence of GVHD, and Outcome
Pt. No. Neu. Eng. PLT Eng.
Acute GVHD
Chronic GVHD Follow-up (m) OutcomeGrade Site
1 No conditioning 0 No 93 Alive and well
2 11 14 0 No 73 Alive and well
3 13 34 0 No 72 Alive and well
4 43 No 2 Skin, GIT No Died, TRM
5 15 28 2 Skin. Liver Limited 30 Alive and well
6 14 37 0 No 25 Alive and well
7 Autologous reconstitution 72 Underwent 2nd Tx from Haploidentical donor. Alive and well
8 12 34 0 No 15 Alive and well
9 24 67 0 No Died, relapse
10 15 68 0 No 11 Alive and well
11 Not engrafted Died, relapse, d + 67
12 Autologous reconstitution in both CB Tx. Rejected after a third Tx from 15 Alive
13 Rejected Died, relapse, d + 120
Rejected
14 26 62 0 0 No 7 Alive and well
15 16 85 0 0 NA NE Autologous backup, alive and well
16 Not eng Died, TRM, d + 22
17 33 102 4 Skin Extensive 17 Died, TRM, d + 517
18 Not eng—second transplantation from Haploidentical donor Died, TRM, d + 314
19 16 NE 0 0 13 Alive, relapsed
20 15 NE 2 Skin 0 8 Alive and well
21 Not eng Died, TRM, d+85
22 Not eng Died, TRM, d+36
23 17 42 1 Skin limited 17.8 Died, relapse
24 Not eng Died, TRM d + 5
25 24 126 0 0 Died, TRM, d + 250
26 24 73 2 Skin 0 9.5 Alive and well
27 36 70 0 0 Died, relapse, d + 144
28 29 76 0 NE 5.8 Alive and well
29 23 44 0 NE 4.5 Alive and well
30 13 40 4 Skin GIT NE 2.5 Died, GVHD d + 102
31 Alive and well
18 Not eng 0 0 NE 2 A&W
ALCL indicates anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, Antithymocytic globulin;
Bu, Busulfan; CAMT, congenital amegakaryocytic; CB, cord blood; CGD, chronic granulomatous disease; CRY, cryopreserved; Cy, cyclophosphamid; d,
days; DCB, double cord blood (from MUDs); dis., discharge; Inf, infused; FA, Fanconi anemia; Flu, fludarabine; HLH, hemophagocytic lymphohistiocytosis;
JMML, juvenile melomonocytic leukemia; Lim, limited; m, months; MDS, myelodysplastic syndrome; Mel, Melphalan; MRD, matched related donor; NE,
not evaluated; URD, unrelated donor; SCID, severe combined immunedeficiency; TBI, total body irradiation; TRM, treatment-related mortality;
Tx,transplantation(s); y, years; WAS, Wiskot Aldrich Syndrome.
Outcomes: Alive and well—15; alive with disease—3; TRM death—9; relapse death—5.
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clonogenicity capabilities upon rehydration. Further-
more, in this novel lyophilization technique there is
no use of toxic cryoprotectans and no thawing pro-
cess (only rehydration); therefore, there is no need
for centrifugation. Hence, cell yield, recovery, and vi-
ability are improved.Ex Vivo Expansion
Additional approach for increasing HUCB-de-
rived stem/progenitor cells is ex vivo expansion. To-
gether with Gamida Cell Ltd., we have developed for
the last 10 years the coppter chelation-based approach.
The results of the Phase I/II clinical trial using the
copper chelator Tetraethylenepentamine (TEPA,
StemEx) for CBT were just published. Currently,
a multicenter international pivotal phase II/III studycomparing d1100 mortality post-CBT using StemEx
versus historical controls is ongoing.
Another alternative strategy we are currently
studying is taking advantage of the multidrug trans-
porter MDR1 (ABCB1) gene product (Pgp) reported
as being overexpressed in various stem cells relative to
their differentiated progeny. We, therefore, com-
pared the expression level and activity of Pgp
in HUCB-derived CD1331 HSCs relative to
CD1332 cells. Moreover, we reasoned that higher
Pgp activity in these CD1331 HSCs will make
them more resistant to cytostatic agents such as col-
chicines (COL), and, thus, its presence during the ex-
pansion process could be applicable to their selection
and enrichment. As more mature cells express lower
levels of MDR relative to the CD1331 cells, in the
prescence of COL, an inhibitor of MDR, it gives
preferential advantage to CD1331 cells to expand
over mature cells. We isolated CD1331 HSCs from
102 Biol Blood Marrow Transplant 15:99-103, 2009A. NaglerHUCB by CD1332 immunomagnetic separation
(MACS). Pgp expression levels were measured by
flow cytometry using the Pgp antibodies MRK-16,
and its activity was measured by accumulation assay
of the Pgp substrate Rh123. We further analyzed
the CD1331/Pgp1 and the CD341/CD382/Pgp1
subsets during 8 weeks of standard cytokine-based ex-
pansion in the presence or the absence of COL. Anal-
yses of freshly isolated CD1331 HSCs from various
donors (n 5 6) indicated that the majority (.92%)
of these HSCs express Pgp on the cell surface. More-
over, the Pgp is functional as the accumulation of
Rh123 was approximately 260-fold lower relative to
CD133 negative cells and the Pgp inhibitor R-VRP
inhibited the efflux of Rh123. Analyses after ex vivo
expansion demonstrated a significant dose-dependent
enrichment of the CD1331 cell fraction by COL. At
the optimal COL dose (2.5 ng/mL), there was 5.2 6
2.3-fold enrichment of CD1331/CD341/CD382
HSC. After 8 weeks of expansion, the CD1331 cell
number increased from 105 cells to 1.6 6 0.4  109
and 0.6 6 0.2  109 in the presence and absence of
COL, respectively. Thus, the total yield of CD1331
HSCs after expansion in the presence of COL was
2.9 6 0.5-fold higher than in its absence. The long
exposure of CD1331HSC to COL during the expan-
sion process did not affect their ability to form
hematopoietic colonies in semisolid cultures. HUCB-
derived HSCs overexpress a functional Pgp that may
be used as a novel tool for their expansion ex vivo to-
ward clinical transplantation.
Boosting Engraftment by Coinfusion of
Mesenchymal Stem Cells (MSCs)
The last approach that we have tried in an attempt
to improve and facilitate engraftment post-HUCB
transplantation is to coadministrate the HUCB cells
with MSCs. We have used the Pluri XTM technology
to expand human placental-derived MSC on 3D car-
riers in a bioreactor (PLX-I) and evaluated its potential
to promoteUCB engraftment in the nonobese diabetic
(NOD)/severe combined immunideficiency (SCID)
mice model. The placental MSCs expressed CD105,
CD73, CD90, and CD29 and lacked expression of
CD45, CD34, and CD19 surface markers. The cells
were capable of differentiation into bone, adipose tis-
sue, and cartilage under specific inductive conditions.
For the next 5 to 6 weeks, a significant increase in %
hCD45 cells were observed in mice cotransplanted
with the placental MSCs cells compared to mice trans-
planted with HUCB CD341 cells alone: 13.6 versus
31.7 (P 5 .01) (n 5 6).
Use of HUCB for Tissue Regeneragion
In addition, we have assessed the potential of
HUCB-derived cells in tissue regeneration for neuro-logic and cardiac applications. In the first set of exper-
iments we were able to demonstrate that neuronal
conditioning medium and nerve growth factor induce
neuronal differentiation of collagen-adherent progen-
itors derived fromHUCB. The aim of the study was to
isolate and characterize a population of neuronal pro-
genitors in the HUCBMNC fraction, for in vitro ma-
nipulation toward neuronal differentiation. Selection
of the HUCB neuronal progenitors (HUCBNPs)
was based on the neuronal prerequisite for adherence
to collagen. Populations of collagen-adherent, nestin-
positive (94.8% 6 2.9%) progenitors expressing
alpha1/2 integrin receptors, as revealed by Western
blot and adhesion assay using selective antagonists,
were isolated and survived for.14 days. In vitro differ-
entiation of the HUCBNPs was achieved by treatment
with 10% human SH-SY5Y neuroblastoma cell-con-
ditioning media (CM) supplemented with 10 ng/mL
nerve growth factor (NGF). Some 83% 6 8.2% of
the surviving progenitors acquired a neuronal-like
morphology, expressed by cellular outgrowths of dif-
ferent lengths. About 35% 6 6% of the HUCBNPs
had long outgrowths with a length/cell diameter ratio
.2, typical of developing neurons. The majority of
these progenitors, analyzed by immunocytochemistry
and/or RT-PCR, expressed common neuronal
markers such as microtubule-associated protein 2
(MAP-2; 98.5 6 2%), neurotrophin receptor (TrkA;
98.5 6 0.06%), neurofillament-160 (NF-160; 94.2 6
1%), beta-tubulin III (89.8 6 4.2%), and neuron
specific enolase (NSE). Combined CM and NGF
treatment induced constitutive activation of the mito-
gen-activated protein kinases ERK2 (36-fold versus
control), p38alpha (ninefold versus control), and
p38beta (23-fold versus control), most likely related
to survival and/or differentiation. The results point
to operationally defined conditions for activating
neuronal differentiation of HUCBNPs ex vivo and
emphasize the crucial role of neuronal CM and NGF
in this process.
Furthermore, we were able to show that HUCB-
derived CD1331 cells enhance function and repair of
the infarcted myocardium. CD1331 progenitor cells
were isolated from newborn HUCB. Cells (1.2-2 
106) or saline (control) was infused intravenously
7 days after permanent coronary artery ligation in
athymic nude rats. Left ventricular (LV) function was
assessed before and 1 month after infusion by echocar-
diography. Tracking of human cells was performed by
fluorescein in situ hybridization (FISH) for human X
and Y chromosomes or by immunostaining for
HLA-DR or HLA-ABC. One month after delivery,
LV fractional shortening improved by 42% 1 17%
in cell-treated hearts and decreased by 39% 1 10%
in controls (P5 .01). Anterior wall thickness decreased
significantly in controls, but not in treated hearts. Mi-
croscopic examination revealed that the HUCB cells
Biol Blood Marrow Transplant 15:99-103, 2009 103Recent Developments in HUCB Transplantation in Israelwere able to migrate, colonize, and survive in the in-
farcted myocardium. Human cells were identified
near vessel walls and LV cavity and were occasionally
incorporated into endothelial cells in six of nine cell-
treated animals but not in controls. Scar tissue from
cell-treated animals was significantly populated with
autologous myofibroblasts as indicated by colocaliza-
tion ofHLA-DR and alpha-smoothmuscle actin stain-
ing, suggesting that, after myocardial infarction (MI),
intravenous delivery of human HUCB-derived
CD1331 cells can produce functional recovery by
preventing scar thinning and LV systolic dilatation.
Moreover, we performed a pilot study demonstrating
the safety and feasibility of intracoronary delivery of
HUCB CD1331 progenitor cells into the infarcted
myocardium of a pig, tracked cell migration, and
colonization. Domestic pigs, weighing 45 kg, were
premedicated and MI was induced by cardiac
catheterization and inflation of a coronary angioplasty
balloon in the left anterior descending (LAD)
coronary artery. The CD1331 progenitor cells were
labeled immediately prior to infusion with [99m]Tc
Exametazime.
The entire cell preparation (20-30  106 in 15-20
mL phosphate-buffered saline [PBS]) was infused dis-
tally to the occluding balloon, through the central port
of the balloon catheter. Whole-body distribution was
recorded 2 h after infusion of the [99m]Tc-labeled
cells and clearly showed that most of the cells colo-
nized in the infarcted myocardium with very low up-
take in the lungs. Four weeks after transplantation
the pigs were sacrificed using a phenobarbital over-
dose. The heart was harvested, sectioned, and pro-
cessed for histology and immunohistochemistry.
Serial sections were immunolabeled with Ab for
HLA and revealed clusters of human cells that colo-
nized and survived in the infarcted myocardium.
HUCB-derived CD1331 cells can thus be delivered
to infarcted myocardium by a catheter-based tech-
nique, and some cells can survive at least 1month with-
out immunosuppression.ACKNOWLEDGMENTS
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